

## RECEIVED

NOV 2 9 2002

TC 1700

Docket No. LFS-0105

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Robert Justice SHARTLE

Serial No.: 09/541,376

Art Unit: 1743

Filed

: 03/31/2000

Examiner: Maureen

Wallenhorst

For

Capillary Flow Control in a Fluidic Diagnostic

Device

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner For Patents, Washington, D.C. 20231 on

November 22 2002 (Date of Deposit)

Jane Silarajs
(Name of applicant, assignee, or Registered Representative)

November 32 2002

(Date of Signature)

Commissioner for Patents Washington, D.C. 20231

## INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §\$1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this

11/27/2002 CV0111 00000025 100750 09541376

180.00 CH

information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

exist.
In accordance with §1.97(b), since this Information
Disclosure Statement is being filed either within three months
of the filing date of the above-identified national application
other than a continued prosecution application under
§1.53(d)), within three months of the date of entry into the
national stage of the above identified application as set forth
in §1.491, or before the mailing date of a first Office Action
on the merits of the above-identified application, or before
the mailing date of a first Office Action after the filing of a
request for continued examination under \$1.114, no additional
fee is required.
In accordance with §1.129(a), this Information
Disclosure Statement is being filed in connection with $\square$ the
first or     second After Final Submission, therefore:
<pre>Statement in Accordance with §1.97(e)</pre>
(attached); or
Please charge Deposit Account No. 10-
0750/ / the fee of $$180.00$ as set forth
in §1.17(p).
In accordance with \$1.97(c), this Information
Disclosure Statement is being filed after the period set forth
in \$1.97(b) above but before the mailing date of either a Final
Action under §1.113 or a Notice of Allowance under §1.311, or
an action that otherwise closes prosecution and that it is
accompanied by one of:

Attached are copies of search report(s) from corresponding patent application(s), which are listed on the attached Submission Under MPEP 609 D.

Attached are the following non-published pending patent applications which may be deemed relevant, which are listed on the attached Submission Under MPEP 609 D.

Please charge any deficiency or credit any overpayment to Deposit Account No. 10-0750/LFS-0105/MM.

Respectfully submitted,

- 11/21/02

Mayumi Maeda

Reg. No. 40,075

Attorney for Applicants

Johnson & Johnson International Patent Law division Attention: Philip Johnson P.O. Box 1222 New Brunswick, NJ 08903

DATED: November 22 2002